Niall O'Donnell is Director at Mirum Pharmaceuticals, Inc. (MIRM). They have made 6 open-market trades across 3 companies since 2019, most recently 2023-05-08.
CIK 0001780235
5 open-market purchases totalling $14.2M since 2019, against 1 sale. Across 5 scored buys the stock is down 11.5% at ninety days, and 17.5 points behind the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 60% | 80% | 20% |
| Avg Move | +7.1% | +5.1% | -11.5% |
| Alpha | +8.7% | +3.1% | -17.5% |
| Scored | 5 | 5 | 5 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| RPHM | BUY | 2023-05-08 | 2023-05-10 | $8.00 | $1.0M | -1.3% | +7.3% | -17.9% |
| SPRB | BUY | 2023-02-16 | 2023-05-16 | $3.17 | $2.0M | +5.2% | +2.2% | -5.2% |
| MIRM | SELL | 2022-11-11 | 2022-11-15 | $19.85 | $11.9M | +1.9% | -8.7% | +20.2% |
| RPHM | BUY | 2021-04-13 | 2021-04-15 | $15.00 | $3.0M | +3.2% | -39.4% | -33.7% |
| SPRB | BUY | 2020-10-14 | 2020-10-16 | $15.00 | $3.8M | +34.0% | +54.9% | +46.9% |
| MIRM | BUY | 2019-07-22 | 2019-07-24 | $15.00 | $4.5M | -5.9% | +0.4% | -47.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.